<DOC>
	<DOCNO>NCT02190786</DOCNO>
	<brief_summary>The purpose study investigate efficacy , safety pharmacokinetics multiple oral administration KUX-1151 patient hyperuricemia include gout .</brief_summary>
	<brief_title>Phase II Exploratory Clinical Study KUX-1151</brief_title>
	<detailed_description />
	<mesh_term>Hyperuricemia</mesh_term>
	<criteria>Japanese HU patient ( Outpatient ) Patients meet follow criterion concern serum uric acid level screen [ 1 ) Gout : &gt; 7.0 mg/dL , 2 ) HU complication : ≥ 8.0 mg/dL , 3 ) HU without complication : ≥ 9.0 mg/dL ] Patients symptom gouty arthritis within 2 week investigational product administration</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hyperuricemia</keyword>
</DOC>